Anti-IgE terapija astme i alergijskog rinitisa omalizumabom by SLAVICA DODIG et al.
INTRODUCTION
Immunoglobulin E (IgE) is fundamental for the development of atopic inflamma-
tory processes and the resulting diseases. Although the role of IgE seems crucial in the
defence against parasites (1), this aspect has not been studied to the extent comparable
to atopy, or only in as much as it may influence the development of atopic disease (2).
Because of the central importance of IgE in asthma and other allergic diseases, research-
ers have long hypothesized that preventing these IgE-mediated processes should reduce
the severity of these disorders. Asthma and allergic rhinitis in particular are clearly re-
lated (3), although much remains to be explained. Up to 60–78% of asthmatics have al-
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The pharmacology, efficacy, dosage, adverse effects, and
economics of anti IgE (omalizumab) are discussed. Oma-
lizumab is the generic name for the human/murine chi-
meric (recombinant humanized) monoclonal IgG antibo-
dy. Anti-IgE prevents IgE from attaching to effector cells,
and thereby blunts IgE-mediated inflammatory responses.
After subcutaneous administration its absorption is slow,
reaching peak concentration in serum after an average of
7–8 days. At recommended doses, serum free IgE levels
decrease within 1 hour following the first dose and are
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add-on therapy in patients with poorly controlled, mode-
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safety profile requires long-term assessment in adults as
well as in children.
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lergic rhinitis and 38% of patients with allergic rhinitis have coexisting asthma (4). Un-
derstanding of asthma and allergic rhinitis has evolved recently the historic perspective
of these allergen-induced disorders as distinct and separate entities is being displaced
by the current thinking that they are better described as a continuum of inflammation
involving one common airway (5). Evidence points to a causal or coincidental relation
between these upper and lower airway diseases (6). Despite effective modern therapies
for these two allergic disorders, involving primarily topical corticosteroids, the frequent
dissapointment with failure to attain treatment goals (7) and their common pathogenetic
origin exemplified by IgE has led to the idea of a »united airway disease« or »one-airway
disease«, lending itself to a comprehensive (»united«) treatment guideline (8). Rather
than following in these footsteps, a monoclonal antibody directed against IgE (omali-
zumab) has been independently developed, anticipating the invoked unitedness of atopic
disease (9). This molecule is a highly specific, highly humanized, non-anaphylactogenic
monoclonal antibody that binds to circulating IgE and prevents it from binding to its re-
ceptors on effector cells. Data so far indicate that omalizumab brings the circulating IgE
to undetectable levels in a dose-dependent fashion. Clinically, it is effective in improving
asthma and allergic rhinitis in patients with and without concomitant pharmacotherapy
and/or conventional immunotherapy (10), and it may have the potential of treating a
wider spectrum of atopic diseases (11) with a very favourable safety profile.
The aim of this article is to review the pharmacology, efficacy, adverse effects and
safety of omalizumab, focusing on the treatment of allergic asthma and allergic rhinitis
in adults as well as in children.
MONOCLONAL ANTI-IgE-ANTIBODY: OMALIZUMAB
Chemistry and function
Omalizumab (brand name: Xolair®) is the generic name for the human/murine chi-
meric (recombinant humanized) monoclonal IgG antibody (Fig. 1). Its molecular mass is
approximately 150 kDa. The specific antibody-binding site, making < 5% of the total mo-
lecule, is of murine origin (variable amino-terminal domains in both heavy and light
chains), whereas the remaining IgG molecule is of human derivation – IgG1 (constant
domains in light  chains and constant domains in heavy  chains, CH1, CH2 and CH3)
(Fig. 1). This confers to the omalizumab two of its most important safety aspects: low-
-immunogenicity due to an extremely low content of murine components, and non-com-
plement binding properties due to the human part of the molecule. Chemically, it is de-
fined as Immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse
monoclonal E25 clone pSVIE26 -chain), disulfide with human-mouse monoclonal E25
clone pSVIE26 -chain, dimer, or as Immunoglobulin G (human-mouse monoclonal E25
clone pSV1E26 -chain anti-human immunoglobulin E Fc region), disulfide with human-
-mouse monoclonal E25 clone pSVIE126 -chain, dimer (12, 13). The binding occurs in
the C3 domain of the IgE molecule, which is also the binding site for the high affinity
IgE receptor. The anti-IgE antibody is needed to block binding of IgE to FcR1 on mast
cells and basophils without crosslinking IgE and triggering degranulation of IgE-sensi-
tized cells, i.e., the antibodies need to be non-anaphylactogenic (14). To achieve this, mo-
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noclonal antibodies against IgE have been developed that bind IgE at the same site as
the high-affinity receptor. Omalizumab-IgE complexes are relatively small, the largest
complexes being hexamers containing three molecules each of omalizumab and IgE (15).
IgE complexed to anti-IgE is unavailable to bind to receptors on IgE effector cells (Fig.
2). It has been reported to decrease serum IgE levels in a dose-dependent manner, inhibit
early allergic reaction (EAR) and late allergic reaction (LAR), and to cause a down-regu-
lation of FcR1 receptors on basophils (16).
The IgE-anti-IgE complexes appear to serve as competitive inhibitors of cell-bound
IgE (mast cells and other effector cells) (17). The downregulation of CD23 may ultima-
tely shift the cytokine milieu away from a T helper cell type 2 proclivity (18) and inter-
rupt the allergenic cascade at its primary step (the binding of allergen-specific IgE to
mast cells). In contrast, other drugs (inhaled corticosteroids, antihistamines, antileuko-
trienes) act at steps in the cascade following mast cell activation and degranulation (19).
It also causes a rapid decrease in dendritic cells surface FcR1 expression and IgE ap-
pears to be an important regulator of FcR1 expression by dendritic cells (20). The anti-
-IgE also removes IgE from the circulation, basophils and mast cells (21, 22).
Pharmacokinetics and pharmacodynamics
Early versions of omalizumab were tested in pilot studies that examined intrave-
nous, subcutaneous and aerosolized administrations. Recently, it culminated in the de-
velopment of a lyophilized product for subcutaneous administration. After subcutane-
ous administration, omalizumab is slowly absorbed (over several days) with an average
absolute bioavailability of 62%. Its absorption is slow, reaching peak concentration in se-
rum after an average of 7–8 days (23–25). The pharmacokinetics of omalizumab is linear
at doses higher than 0.5 mg kg–1. Following multiple doses of omalizumab, areas under
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Fig.1. Chimeric antibody made of both mouse and human antibodies.
Fig. 2. Anti-IgE binds free IgE.
the serum concentration-time curve from day 0 to day 14 at steady state are up to 6-fold
of those after the first dose (26). The volume of distribution is 78 ± 32 mL kg–1, approxi-
mating the plasma volume, and the half-life is about 26 days, with apparent clearance
averaging 2.4 ± 1.1 mL kg–1 day–1. Clearance of the omalizumab-IgE complex from the
body proceeds like IgG clearance processes, i.e., by liver elimination, which includes
degradation in the liver reticuloendothelial system (RES) and endothelial cells and ex-
cretion in bile. The omalizumab-IgE complexes have a serum half-life of approximately
20 days (27). The half life of omalizumab-IgE complexes in the blood is about 26–28 days
(25, 26).
At recommended doses (Table I), total serum IgE (omalizumab-IgE complex and
free IgE, i.e., bound and unbound) concentration increases after the first dose due to the
formation of omalizumab-IgE complexes, which have a slower elimination rate com-
pared with free IgE. Sixteen weeks after the first dose, total IgE levels were 5-fold higher
than baseline levels. On the other hand, serum free IgE decreased in a dose dependent
manner within 1 hour following the first dose and remained at this level between the
doses. Finally, as a result of complex formation, the concentration of total IgE in serum is
increased, and concentration of free IgE is decreased. In such a manner, total IgE levels
do not return to pre-treatment levels for up to 1 year after discontinuation (24, 25).
DOSAGE AND ADMINISTRATION
Suppression of free IgE is deemed to be necessary for optimal efficacy (25). Dose
and dosing frequency are adjusted according to body mass and serum total IgE concen-
tration pretreatment (Table I). Corne et al. (24) investigated the correlation between the
dose of anti-IgE and serum IgE concentration. The intravenous dose of 3 mg of anti-IgE
antibody resulted in a decrease of serum free IgE from 495.8 kIU L–1 (pretreatment va-
lue) to 53.8 kIU L–1, and the administration of 100 mg of anti-IgE antibody caused sup-
pression of total serum IgE from 2317 kIU L–1 to 7.3 kIU L–1, respectively. Time of recovery
ranged from 1 day (for the 3 mg dose) to 39 days (for the 100 mg dose) (24). Therefore,
therapeutic monitoring of free IgE levels during anti-IgE treatment appears to be a desir-
able tool (24, 28). The monthly dose is calculated according to the next formula (19):
0.016  body mass (kg)  serum total IgE (kIU L–1) = monthly dose of omalizumab (mg)
A hypothetical 70-kg patient with an IgE concentration of 700 kIU L–1 would requ-
ire 0.016  70  700 = 784 mg per month, a 50-kg patient with an IgE concentration of 300
kIU L–1 would require 240 mg per month, and a 85-kg patient with an IgE concentration
of 500 kIU L–1 would require 680 mg per month. Owing to the volume of injection, oma-
lizumab doses higher than 300 mg per month must be given in divided doses every 2
weeks. No more than 150 mg is injected at a single site. Some owerweight patients or who
have very high IgE concentrations (> 700 kIU L–1 for adults and > 1300 kIU L–1 for chil-
dren) or both may not be able to receive omalizumab. In such patients, the calculated
dose would be too large to be given in two subcutaneous injections per month. At pres-
ent, omalizumab cannot be administered to patients requiring more than 750 mg per
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month. Repeated determination of serum IgE concentration cannot be used to adjust the
dose, as total concentrations (when using standard assays), which measure both the oma-
lizumab-IgE complex and free IgE, are elevated (26).
In view of the risk of anaphylaxis, it is recommended that omalizumab be given in
the office of a physician capable of treating anaphylaxis. The patients should be observ-
ed for a period of time before leaving the office (19).
CLINICAL OUTCOME
Omalizumab is not a first-line therapy in asthmatic patients. FDA approved oma-
lizumab use in June of 2003 for patients satisfying the following criteria (all must be pre-
sent):
(i) total IgE concentration in serum 30–700 kIU L–1: if IgE is < 30 kIU L–1, there is too
little substrate for the anti-IgE to bind, if IgE is > 700 kIU L–1 (> 1300 kIU L–1 in chil-
dren), the volume of the omalizumab injection needed will be too large;
(ii) skin test positive for at least one perennial allergen;
(iii) specific IgE concentration positive for at least one perennial allergen (house dust
mite, cat and dog);
(iv) asthma: moderate to severe persistent asthma;
(v) age:  12 years;
(vi) inadequate control despite inhaled corticosteroids.
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Table I. Proposed dose regimen charts from the package inserta
Baseline
IgE (kIU L–1) Body mass (kg)
30–60 > 60–70 > 70–80 > 80–90 > 90–150
 30–100 150 150 150 150 300
> 100–200 300 300 300 300
> 200–300 300




> 100–200 ADMINISTRATION EVERY 4 WEEKS 225
> 200–300 225 225 225 300
> 300–400 225 225 300 300
> 400–500 300 300 375 375
> 500–600 300 375 DO NOT
> 600–700 375 DOSE
a XOLAIR doses (in mg) for subcutaneous administration to adults and adolescents (patients with allergic
asthma  12 years of age) (25).
Omalizumab is used for the management of moderate to severe persistent asthma
in adults and adolescents 12 years of age and older. An algorithm of asthma care includ-
ing omalizumab is presented in Table II (19). Omalizumab should be considered for pa-
tients in any of the next categories: whose symptoms are inadequately controlled with
inhaled corticosteroids, namely those with persistent and significant symptoms or rever-
sible airflow obstruction as measured by spirometry; those dependent on oral steroids;
those on multiple-drug asthma therapy (e.g., inhaled corticosteroids combined with a
long-acting beta-agonist, a leukotriene modifier drug or theophylline), those who have
had adverse effects from corticosteroids, or are at increased risk of them (19, 29). Oma-
lizumab is recently used in children younger than 12 years (16). It is reported that oma-
lizumab has been also approved for the treatment of allergic rhinitis. Patients with pol-
lenosis have a seasonal increase of both total and specific IgE concentration in serum.
This increase would have no impact on omalizumab doses in the majority of patients.
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Table II. Omalizumab in an algorithm of asthma carea
CONFIRM DIAGNOSIS OF ASTHMA DETERMINE LEVEL OF ASTHMA SEVERITY AND
CONTROL












Low or moderate dose
ICS plus LAA plus,
as needed, SAA, or
(not preferred) low or





LAA plus, as needed,




If control is adequate, schedule regular follow-up
If control is inadequate, as follows:
Add low-dose ICS Add LAA Re-assess for asthma
triggers
Consider referral to an
asthma specialist
Change to high-dose ICS










Consider referral to an
asthma specialist
Change to high-dose






ICS – inhaled corticosteroid
ISAA – inhaled short-acting beta-agonist
SAA – short-acting beta-agonist
LAA – long-acting beta-agonist
a According to ref. 19.
Individual variations, however, can be large and require a dose correction (28). Many
asthmatics, morever, have additional sensitisations against seasonal pollen-allergens, and
seasonal exposure may increase total and specific IgE levels. Those patients sometimes
require additional administration of omalizumab (28).
Results of clinical trials demonstrated that omalizumab administered subcutane-
ously is an effective treatment for add-on therapy in patients with poorly controlled,
moderate-to-severe allergic asthma (23, 30, 31), as well as for patients with allergic rhini-
tis (32, 33). In most patients, the dosing formula will lead to prescribing enough anti-IgE
to bind over 98% of free IgE (34). To achieve effective treatment, patients should be tre-
ated with omalizumab for a minimum duration of 12 weeks (35). Omalizumab’s ability
to form complexes with unbound IgE translates into decreased unbound serum IgE lev-
els and high-affinity IgE receptors on basophils, as well as attenuation of early and late
allergic response in patients with allergic diseases. A marked reduction in circulating
free IgE levels has been shown to reduce symptoms in those patients (36). Milgrom et al.
(16) reported that the median concentration of free IgE in serum decreased significantly
(95–99%) in the omalizumab treated children aged 6 to 12 years (from 133 to 790 kIU L–1
at baseline to 6 to 9 IU L–1 during the treatment period).
Studies in asthma
Treatment protocols were conducted in Europe and the United States in moderate to
severe allergic asthmatic patients who continued to show symptoms despite treatment
with inhaled corticosteroids. At present, the peer-review published double-blind, place-
bo-controlled studies showed that treatment with anti-IgE allowed a decrease in inhaled
corticosteroid and rescue medication use and significantly reduced the incidence and
frequency of asthma exacerbations among the patients (37). One of the core studies in
moderate to severe allergic asthmatics mean Forced Expiratory Volume in 1st second
(FEV1) at baseline 70%) showed, over a 7-month period, a decrease of asthma exacerba-
tion rate for more than 50% during the stable steroid phase (16 weeks) as well as during
the phase of inhaled steroids reduction (38). The double-blind placebo-controlled exten-
sion of this study by 24 weeks demonstrated a significant improvement in the asthma
related quality of life over placebo (39). In a further article, the same authors analyzed
long-term effects of omalizumab on the same subjects that were now entered into the
double-blind extension trial (40). The asthma control was improved despite significantly
lower daily inhaled steroid dosage (253 g vs. 434 g beclomethasone per day): asthma
exacerbation rate was more than halved on omalizumab, concomitant medication use
was significantly lower, while the incidence of adverse events was similar in the two
groups. A further 12-months double-blind placebo-controlled study of moderate to se-
vere allergic asthma in subjects 12 years and older confirmed the add-on value of oma-
lizumab to the best standard treatment (31). In addition to halved exacerbation rates and
significantly reduced rescue medication, this study demonstrated a significant increase
in FEV1 of 0.2 L (from average 2.28 to 2.48 L). The SOLAR study was designed to exam-
ine the benefit of omalizumab in patients 12 years and older with moderate to severe al-
lergic asthma and concomitant persistent allergic rhinitis over 28 weeks in a randomized
double-blind placebo-controlled fashion (41). The drug was well tolerated and produced
a decrease in asthma exacerbation rate by a factor of 1.5. Simultaneously, it improved the
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asthma and rhinitis related quality of life and the asthma/rhinitis composite symptom
score. The baseline treatment of the patients was not changed and was required to be
> 400 g budesonide via Turbuhaler at study entry. Other studies have equally demon-
strated that omalizumab allows reduction of inhaled steroid dose (beclomethasone or
equivalent 227 g vs. 336 g per day) while maintaining improved asthma control (30%
decrease in exacerbation rate over placebo) (30). As Rambasek et al. (19) reported, it is
unclear if the clinically meaningful benefit observed in patients on moderate-dose in-
haled corticosteroids would also occur in sicker patients on high-dose inhaled cortico-
steroids plus long-lasting beta-agonists (population to which omalizumab is, at present,
most directed). In patients randomized to receive either omalizumab or placebo, Hol-
gate et al. (42) reported that patients who were primarily using high doses of inhaled
corticosteroids (fluticasone, average dose > 1.3 mg per day) could significantly reduce
the inhaled dose (42).
Djukanovic et al. (43) investigated the influence of omalizumab on airway inflam-
mation. Outcomes included inflammatory cells in induced sputum and bronchial biopsies,
and methacholine responsiveness. Sixteen weeks treatment with omalizumab resulted in
a marked reduction of serum IgE. Diminished number of eosinophil granulocytes was
associated with a significant reduction in tissue eosinophils, FcepsilonRI+ cells, CD3+,
CD4+ and CD8+ T lymphocytes, B lymphocytes, and cells staining for IL-4+ but not
with improvement in airway hyper-responsiveness to methacholine. This study showed
anti-inflammatory effects of omalizumab. The lack of effect of omalizumab treatment on
methacholine responsiveness suggests that IgE or eosinophils may not be causally link-
ed to airway hyper-responsiveness to methacholine in mild to moderate asthma (43).
Studies in seasonal allergic rhinitis
Multiple investigations have shown omalizumab to be an effective agent in IgE-me-
diated allergic rhinitis (32, 44, 45). The main outcome measures were the increased IgE
concentration in serum as well as the self-assessed daily nasal symptom severity score
and the frequency of rescue antihistamine use. The nasal symptom scores were signifi-
cantly lower with the 300-mg dose of omalizumab (44). Nayak et al. (46) found omali-
zumab to improve the rhinitis-specific quality of life. Omalizumab appeared to be a well
tolerated agent (28, 29), even in retreatment during a second ragweed pollen season (46),
although the safety profile requires a longer-term assessment (41). It was clearly shown
that a 16-week omalizumab treatment in patients with allergic rhinitis almost fully at-
tenuates nasal symptoms on allergen challenge, stops albumin exudation and signifi-
cantly reduces tumor necrosis factor alpha (TNF-alpha) in nasal lavage fluid (44). Inter-
estingly, the histamine content of the nasal lavage fluid remained unaffected. Significant
blunting of clinical nasal symptoms can be expected within 2 weeks of the first dose of
omalizumab (47). Elimination of 96% of free IgE occurs within 3 days, and downregu-
lation of 73% of high-affinity-epsilon-receptor FcERI on basophils within 14 days.
Studies in children
FDA has approved omalizumab use only for patients aged 12 years or older, al-
though the core study was conducted on children 6–12 years of age (16). This study has
shown, similarly to the studies in adults, that regular omalizumab therapy allows signifi-
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cant inhaled steroid dose reduction while maintaining protection against exacerbation.
Further investigation of the subjects in the aforementioned study has established a signi-
ficant improvement in the asthma related quality of life (48). Another study has confirmed
that these clinical effects are accompanied by improvement in the markers of inflamma-
tion (49). The results showed that treatment with omalizumab may inhibit airway in-
flammation during steroid reduction in children with allergic asthma measured by a sig-
nificant decrease of exhaled nitric oxide from pretreatment 41 ppb to 18 ppb in week 52
of treatment, despite concurrent decrease in the dose of inhaled steroids.
Berger et al. (50) evaluated the long-term (52-week) safety profile. They found that
the safety and tolerability of omalizumab in children was largely comparable to placebo
(the most common adverse event was upper respiratory infection: 47% in omalizumab
vs. 43% in the placebo group, not siginficant). Patients in the omalizumab group exhi-
bited urticaria in 4.9% of patients, which was generally well controlled with antihistami-
ne treatment, and resulted in withdrawal from treatment in only 1 out of 11 patients.
It has also been shown that children with seasonal allergic rhinits can benefit from
omalizumab in terms of significant reduction of symptoms (48% over specific immuno-
therapy alone), steroid and rescue medication use when used in combination with specific
immunotherapy (51). Reduction in ex vivo leukotriene release from peripheral leukocyte
on specific allergen challenge in the treated subjects seemed to parallel the clinical ef-
fects (52). However, the quantification of endogenous leukotrienes in urine produced
equivocal results (53).
According to the Omalizumab Rhinitis Study Group, anti-IgE monotherapy signifi-
cantly diminished rescue medication use and number of symptomatic days in children
aged 6–17 years with seasonal allergic rhinitis. The combination of anti-IgE and specific
immunotherapy showed superior efficacy to each treatment alone during the first year
of observation (32). The combination of specific ummunotherapy (SIT) and anti-IgE in
children with seasonal allergic rhinoconjunctivitis is associated with prevention of nasal
specific immunotherapy (ECP) increase and decreased tryptase levels in nasal secretions
(33). The results were similar to those seen for inhaled corticosteroids alone, meaning
that omalizumab has significant antiinflammatory effects (49). Omalizumab reduces leu-
kotriene (LT) release of peripheral leukocytes stimulated in vitro with allergen in chil-
dren with allergic rhinitis undergoing allergen immunotherapy, but urinary LTE4 con-
centrations are not helpful in monitoring patients treated with anti-IgE and SIT (53).
TOLERABILITY AND SAFETY
The limited clinical data currently available suggest that anti-IgE treatment with
omalizumab did not cause any of the complications that might, in theory, be expected to
result from a reduction in circulating free IgE, such as adverse effects upon the immune
system or other body systems (54). According to some reviewers, the results of clinical
trials demonstrated that omalizumab administered subcutaneously is a safe and effec-
tive treatment for moderate to severe allergic asthma, since it generally has a mild ad-
verse effect profile (23, 24, 30). In patients with seasonal allergic rhinitis there are no se-
vere or serious adverse events related to omalizumab treatment. Retreatment during a
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second pollen season with omalizumab, 300 mg every 3 or 4 weeks, was not associated
with any significant immunologic reactions (46). There are many documented clinical
adverse events as well as laboratory arguments that can be classified in several groups:
most frequent (injection-site reactions, viral infections), severe (malignancy), rare (rash)
and laboratory (decreased hemoglobin) (Table III) (41, 46, 55, 56). Besides, the safety pro-
file requires long term assessment (28, 29).
The most frequent adverse events in asthma patients receiving omalizumab include
injection-site reactions (45%), viral infection (23%), upper respiratory tract infection (20%),
sinusitis (16%), pharyngitis (11%), or headache (15%). Injection-site reactions include red-
ness, warmth, burning, stinging, itching, hive formation, pain induration, and inflam-
mation. The local reaction, that usually occurs within one hour of the injection, lasts up
to 8 days (24). Randomized placebo-controlled studies indicate that omalizumab dis-
plays a very favourable safety profile when used for treatment of asthma in adults (31,
41) as well as in children (16). Almost 17% patients receiving anti-IgE experienced ad-
verse effects (compared to 12% in placebo group). Serious adverse events were recorded
in 1.4% of the omalizumab group (1.5% in placebo group) (25, 26). The proportion of
subjects experiencing events such as headache, pharyngitis, sinusitis, influenza, upper
respiratory tract infection and bronchitis did not differ significantly from the placebo
group. The principal adverse events judged to be drug related were injection site reac-
tions (7–8% vs. 4–5%) and urticaria (1–2% vs. 0–1%).
No patient developed anti-omalizumab antibodies and there was no evidence of
immune complex disease (31). According to Berger et al. (50), there is no evidence that
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Table III. Adverse events of omalizumab administrationa
Most frequent adverse events Injection-site reactions
Viral infection








Events among the geriatric population
Severe events Malignancy
Anaphylaxis
Clinical laboratory arguments Decreased hemoglobin
Thrombocytopenia
Mild leukocyte decrease
a According to refs. 25, 26, 28, 29.
new or more serious adverse events occur with long-term omalizumab treatment in chil-
dren. No anti-omalizumab antibodies were detected in any of the children (50).
The most noteworthy serious adverse events are malignancy and anaphylaxis. Sub-
cutaneous injections with a monoclonal anti-immunoglobulin E antibody for ragweed or
birch allergic rhinitis produced few anaphylactic reactions but when reactions did occur,
they appearred 90–120 minutes after the injection (57).
It is not known whether IgE plays a surveillance role in cancer prevention, though
there is evidence of its role in protection from a variety of environmental carcinogens
and infectious diseases (58). Malignancies appear to be observed less frequently in the
closest relatives of patients suffering from hay fever with the documented hereditary lia-
bility to atopy than in the relatives of control groups (59). It was recently documented
that the history of asthma and hay fever were associated with a trend toward a reduced
risk of colorectal cancer and increased risk of leukemia, but these results were not statis-
tically significant. No association was found between breast and lung cancers and aller-
gic disorders or atopy (59).
If IgE is blocked (with anti-IgE antibody), there is a theoretical question of whether
there is an associated increase in cancer incidence. According to Vignola et al. (41), seri-
ous adverse events were observed in 1.4% of omalizumab-treated patients and 1.5% of
placebo-treated patients. In the studies that were submitted to obtain FDA approval, the
incidence of new or recurrent cancer was 0.5% with omalizumab and 0.2% with placebo.
The types of malignancies observed included breast, melanoma, non-melanoma skin,
prostate, and parotid. Most patients were observed for less than a year (25). Consequ-
ently, a shorter period than that in which oncogenesis can be usually observed, and be-
cause the tumors involved various organs, it is reasonable to doubt that these cancers
were caused by omalizumab. It is unknown if longer exposure or use in patients with
higher risk factors for malignancy increases the risk of developing cancer. On the other
hand, there are no published data that provide a direct pathophysiological link between
anti-IgE therapy and cancer development or progression, but the potential for alterati-
ons in the function of IgE-mediated effector cells (mast cells, eosinophil granulocytes)
must be considered. Alteration of these functions by anti-IgE therapy may, theoretically,
affect the resistance to cancer.
Influence on laboratory findings
In general, clinical laboratory data are most remarkable for the decreased hemoglo-
bin concentration and mild platelet counts in some patients. In animal studies (with high
doses of omalizumab), serum omalizumab concentrations correlate most closely with
platelet decrease. The doses used in clinical studies were considerably lower than those
associated with thrombocytopenia in animals. The observed decreased leukocyte num-
ber was low and clinically inconsequential. In general, these events were associated with
viral-type illnesses or were isolated time point findings. No subject developed persistent
neutropenia and no subject experienced a decrease in white blood cells count below
2.3  109 per litre.
A Cochrane meta-analysis of eight trials involving 2037 mild to severe asthmatic pa-
tients pointed to the conclusion that omalizumab was well tolerated, but the safety pro-
file required longer-term assessment in adults as well in children (55, 56)
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COST ANALYSIS
Biological agents are expensive to produce. Omalizumab is far more expensive than
other asthma medications. The average wholescale price of omalizumab will be $433 per
vial, putting the annual cost per patient at roughly $10,000 to $12,000 (60, 61). Children
tend to need higher doses as they usually have higher IgE levels. A calculation of the
cost of co-seasonal application of an average 0.016 mg per kg per IU IgE per month in
children 6–17 years of age with hay fever yielded a mean of 1253  per patient per month
which, compared to specific immunotherapy (425  in the first year of treatment) was
more expensive, but also significantly more effective (32). A retrospective economic ana-
lysis was performed to determine the cost-effectiveness of omalizumab using 52-week
data from 2 randomized controlled clinical trials in adults and adolescents with moder-
ate-to-severe allergic asthma. Only direct costs were considered. Omalizumab adminis-
tration could be cost-saving if given to nonsmoking patients who are hospitalized 5 or
more times or 20 days or longer per year despite maximal asthma therapy with older
drugs (61). The dosage of omalizumab depends on the patient’s body mass and serum
IgE concentration, meaning that a small patient with slightly elevated IgE might require
one vial per month ($5,196 per year); a larger patient with an IgE concentration of 600
kIU L–1 could require as many as five vials per month ($25,980 per year) (19) The high
cost associated with omalizumab treatment may be prohibitive for some patients, the-
reby limiting its utility (23). Omalizumab could be cost-effective for patients with sea-
sonal asthma, since it would not need to be used year-round (19).
FUTURE RESEARCH
Despite many studies addressing the role of anti-IgE antibody in patients with aller-
gic diseases of airways, a number of questions remain:
(i) Is it beneficial in less than severe or moderate asthma?
(ii) Can it prevent the onset of asthma in patients with allergic rhinitis?
(iii) Is it going to have a role in childhood asthma?
(iv) Can it prevent airway remodeling?
(v) Does it facilitate specific immunotherapy?
(vi) Can it be used in food allergy?
(vii) What effect does it have on atopic dermatitis?
(viii) Is it effective in nonatopic asthma?
Also, it remains to be determined whether omalizumab might be beneficial to patients
with intrinsic asthma, who may also overexpress FcR1receptors within their bronchial
mucosa (62).
Symbols. – CD – Cluster of Differentiation; EAR – Early Allergic Reaction; ECP – Eosinophil
Cationic Protein; Fc – Fc-fragments; FcR1 – High-affinity-Epsilon-Receptor; FEV1 – Forced Expiratory
Volume in 1st second; ICS – Inhaled Corticosteroid; IgE – Immunoglobulin E; IgG – Immunoglobulin
G; IL – Interleukin; ISAA – Inhaled Short-Acting Beta-Agonist; LAA – Long-Acting Beta-Agonist;
LAR – Late Allergic Reaction; LT – Leukotriene; RES – Reticuloendothelial System; SAA – Short-
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-Acting Beta-Agonist; SIT – Specific Immunotherapy; SOLAR-study – Study on Occupational Al-
lergy Risks; TNF-alpha – Tumor Necrosis Factor Alpha
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S A @ E T A K
Anti-IgE terapija astme i alergijskog rinitisa omalizumabom
SLAVICA DODIG, DARKO RICHTER, IVANA ^EPELAK i BOJAN BENKO
Opisani su farmakologija, djelotvornost, doziranje, nuspojave i ekonomi~nost prim-
jene anti IgE antitijela – omalizumab. Omalizumab je generi~ko ime za ljudsko/mi{je ki-
meri~no (rekombinantno humanizirano) monoklonalno IgG antitijelo. Anti-IgE sprje~ava
vezanje IgE na efektorske stanice i sprje~ava upalni odgovor posredovan s IgE. Nakon
subkutane primjene sporo se apsorbira te dosti`e vr{nu koncentraciju u serumu nakon 7
do 8 dana. Uz preporu~ene doze koncentracija slobodnoga IgE u serumu smanjuje se
unutar jednoga sata. Doziranje se pode{ava prema tjelesnoj masi i koncentraciji IgE-a u
serumu. Omalizumab je djelotvoran kao dopunska terapija u pacijenata (starijih od 12
godina) sa slabo kontroliranom umjerenom do te{kom alergijskom astmom odnosno s
alergijskim rinitisom. Smanjuje potrebu za inhalacijskim kortikosteroidima te pogor{a-
nje astme. Dobro se podnosi, ali sigurnost primjene, kako u odraslih tako i u djece, treba
jo{ ispitati.
Klju~ne rije~i: astma, alergijski rinitis, terapija, anti-IgE, omalizumab
Dje~ja bolnica Srebrnjak, Zagreb
Farmaceutsko-biokemijski fakultet, Zagreb
Dr`avni zavod za intelektualno vlasni{tvo, Zagreb
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